… Other drugs, with either inhibitory effects on Tx synthase or … providing a better, more
complete inhibition of the TxA 2 pathway. … pathway as a target for antiplatelet drug therapy. …

… Inhibitors of arachidonic acid metabolism and thromboxane … inhibit cyclooxygenase, and
thromboxane synthase inhibitors. … initiation of only one of several pathways of I)latelet activation. …

… inhibition can be achieved either by blockade of membrane receptors or by interaction with
intracellular signalling pathways. … Antiplatelet therapy is the mainstay of treatment of patients …

… Combined antiplatelet therapy, with dual targeted inhibition of the platelet cyclooxyenase-1
pathway (… Rates of bleeding increase with the prolonged duration of dual antiplatelet therapy, …

… It was proposed that inhibitor of Gq signaling pathway of platelet adhesion will inhibit
platelet aggregation by interfering with the GDP-GTP exchange pathway and blocking P2Y1 …

… treatment regimen (dual antiplatelet therapy (DAPT) and dual pathway antithrombotic …
Increasing the intensity of antiplatelet therapy by combining aspirin with P2Y 12 inhibitors has …

… in antiplatelet therapy. In … antiplatelet pathway inhibition is more than additive in preventing
thrombus formation. Several trials are planned or are ongoing with dual antiplatelet therapy. …

… COX-1 inhibition achieved with aspirin. Further, many TXA 2 pathway inhibitors also exert
inhibitory effects on … TXA 2 pathway inhibitors include picotamide (a combined TXA 2 synthase …

… pathways that could be inhibited by using antiplatelet agents which target rising Ca+2 levels
dependent to GPRC signalling pathways… antiplatelet therapy based on: 1) direct inhibition of …

… Advances in antiplatelet therapies for patients with cardiovascular disease have improved …
risk of ischaemic events despite receiving antiplatelet therapy. Therefore, novel strategies are …